Compound 28 / HaiHe Biopharma, Shanghai Haishi Biopharma - LARVOL DELTA

Expert Perspectives on Emerging CDK4/6 Inhibitor Strategies in Advanced Prostate Cancer Management Settings (Physicians' Education Resource) - "7:30 PM - 7:40 PM, Welcome and Introductions; 8:25 PM - 8:45 PM, Role of CDK4/6 Inhibitors in CSPC and CRPC Treatment: Panel Discussion; 8:45 PM - 8:55 PM, Audience Q and A; 8:55 PM - 9:00 PM, Summary and Conclusions."

CME